select a format

Single User License
USD 2000 INR 128900
Site License
USD 4000 INR 257800
Corporate User License
USD 6000 INR 386700

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Botulism-Pipeline Review, H2 2015

Botulism-Pipeline Review, H2 2015


  • Products Id :- GMDHC6891IDB
  • |
  • Pages: 41
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Botulism-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Botulism-Pipeline Review, H2 2015', provides an overview of the Botulism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Botulism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Botulism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Botulism

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Botulism and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Botulism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Botulism pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Botulism

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Botulism Overview 6

Therapeutics Development 7

Pipeline Products for Botulism-Overview 7

Pipeline Products for Botulism-Comparative Analysis 8

Botulism-Therapeutics under Development by Companies 9

Botulism-Therapeutics under Investigation by Universities/Institutes 10

Botulism-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Botulism-Products under Development by Companies 13

Botulism-Products under Investigation by Universities/Institutes 14

Botulism-Companies Involved in Therapeutics Development 15

AlphaVax, Inc. 15

Hawaii Biotech, Inc. 16

Molecular Targeting Technologies, Inc. 17

XOMA Corporation 18

Botulism-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

BoNT/A HcR4-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

botulinum vaccine-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

botulinum vaccine-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

botulism vaccine-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

botulism vaccine-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibodies to Inhibit Botulinum Neurotoxin for Botulism-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Recombinant Peptides to Inhibit Botulinum Toxin for Botulism-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules for Botulism-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

XOMA-3-AB-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Botulism-Recent Pipeline Updates 36

Botulism-Dormant Projects 37

Botulism-Discontinued Products 38

Botulism-Product Development Milestones 39

Featured News & Press Releases 39

May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

Number of Products under Development for Botulism, H2 2015 7

Number of Products under Development for Botulism-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

Products under Investigation by Universities/Institutes, H2 2015 14

Botulism-Pipeline by AlphaVax, Inc., H2 2015 15

Botulism-Pipeline by Hawaii Biotech, Inc., H2 2015 16

Botulism-Pipeline by Molecular Targeting Technologies, Inc., H2 2015 17

Botulism-Pipeline by XOMA Corporation, H2 2015 18

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Stage and Target, H2 2015 20

Number of Products by Stage and Mechanism of Action, H2 2015 21

Number of Products by Stage and Route of Administration, H2 2015 23

Number of Products by Stage and Molecule Type, H2 2015 25

Botulism Therapeutics-Recent Pipeline Updates, H2 2015 36

Botulism-Dormant Projects, H2 2015 37

Botulism-Discontinued Products, H2 2015 38

List of Figures

Number of Products under Development for Botulism, H2 2015 7

Number of Products under Development for Botulism-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Early Stage Products, H2 2015 12

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Stage and Top 10 Targets, H2 2015 20

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 21

Number of Products by Top 10 Routes of Administration, H2 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 22

Number of Products by Top 10 Molecule Types, H2 2015 24

Number of Products by Stage and Top 10 Molecule Types, H2 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AlphaVax, Inc.

Hawaii Biotech, Inc.

Molecular Targeting Technologies, Inc.

XOMA Corporation

Botulism Therapeutic Products under Development, Key Players in Botulism Therapeutics, Botulism Pipeline Overview, Botulism Pipeline, Botulism Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com